Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Stocks in this Quantisnow insightHealth Care
Historical context for SKYE
Across the 6 sessions after earlier SKYE headlines, the stock closed higher 4 times and lower 2 times, with a median move of 4.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SKYE | SPY |
|---|---|---|---|
| Jan 29, 2026 | Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference | -5.0% | -0.2% |
| Jan 21, 2026 | Skye Bioscience to Present Poster at Keystone Obesity Conference | +0.8% | +1.2% |
| Jan 12, 2026 | Skye Provides 2026 Corporate Outlook | -4.0% | +0.2% |
| Nov 24, 2025 | Skye Bioscience to Participate in Upcoming Investment Conferences | +11.6% | +1.5% |
| Nov 11, 2025 | Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update | +2.8% | +0.2% |
| Nov 5, 2025 | Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gainand 1 other headline that session | +6.3% | +0.3% |
Quantisnow market dataNASDAQ
SKYE
Skye Bioscience Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for SKYE
Full SKYE profile on Quantisnow Follow SKYE and get a push notification the moment its next story breaks.